XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business AchievementsGlobeNewsWire • 03/17/25
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/04/25
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesGlobeNewsWire • 11/07/24
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in CashBusiness Wire • 10/22/24
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceGlobeNewsWire • 10/22/24
Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)GlobeNewsWire • 09/23/24
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent ActivitiesGlobeNewsWire • 08/13/24
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review VoucherGlobeNewsWire • 06/12/24
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQGlobeNewsWire • 05/14/24